Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512380 | 1.00 | LMNA (0.48) | LMNASMN1; SMN2KEAP1NFE2L2IDO1 | |
| SCHEMBL30004306 | 0.81 | KEAP1 (0.44) | LMNASMN1; SMN2KEAP1NFE2L2IDO1 | |
| SCHEMBL714234 | 0.80 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL714235 | 0.80 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29665643 | 0.80 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2331584 | 0.78 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2331329 | 0.78 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2331330 | 0.78 | ALDH1A1 (0.46) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL298855 | 0.77 | CA12 (0.54) | LMNASMN1; SMN2KEAP1ALDH1A1MEN1 | |
| SCHEMBL42287 | 0.77 | CA12 (0.54) | LMNASMN1; SMN2KEAP1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197899-B1 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA- BETA3-AMINOACYL RESIDUE AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2014-09-03 | — | — | EP | claimed |
| US-8603968-B2 | Cyclic peptides comprising at least one aza-β3-aminoacyl residue and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-10 | — | — | US | claimed |
| US-20100305027-A1 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-B3-AMINOACYL RESIDUE AND THEIR USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-02 | — | — | US | claimed |
| EP-2197899-A2 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA- BETA3-AMINOACYL RESIDUE AND USES THEREOF | Centre National de la Recherche Scientifique (FR) | 2010-06-23 | — | — | EP | claimed |
| WO-2009083663-A2 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-Β3-AMINOACYL RESIDUE AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-07-09 | — | — | WO | claimed |
| EP-2197899-B1 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA- BETA3-AMINOACYL RESIDUE AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-8603968-B2 | Cyclic peptides comprising at least one aza-β3-aminoacyl residue and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-10 | — | — | US | disclosed |
| US-20100305027-A1 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-B3-AMINOACYL RESIDUE AND THEIR USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-02 | — | — | US | disclosed |
| EP-2197899-A2 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA- BETA3-AMINOACYL RESIDUE AND USES THEREOF | Centre National de la Recherche Scientifique (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009083663-A2 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-Β3-AMINOACYL RESIDUE AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305027-A1 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-B3-AMINOACYL RESIDUE AND THEIR USES | NPR3, VIP, ANPEP | LMNA 3734/4885SMN1; SMN2 4302/4885KEAP1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.